(Q40489194)

English

Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

piperacillin/tazobactam

1 reference

based on heuristic

inferred from title

author name string

Harter C

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Schulze B

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Goldschmidt H

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Benner A

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Geiss HK

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hoppe-Tichy T

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Ho AD

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Egerer G

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

373-379

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

Perspectives for the management of febrile neutropenic patients with cancer in the 21st century

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

21 January 2018

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

7 January 2021

based on heuristic

inferred from DOI database lookup

Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of antibiotics in cancer and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705256

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705256

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40489194&oldid=2203731426"